The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Effect of Aspirin on All-Cause Mortality in the Healthy Elderly
Open accessAbstract
BACKGROUND: In the primary analysis of the Aspirin in Reducing Events in the Elderly (ASPREE) trial, now published in the Journal, we report that the daily use of aspirin did not provide a benefit with regard to the primary end point of disability-free survival among older adults. A numerically higher rate of the secondary end point of death from any cause was observed with aspirin than with placebo. METHODS: From 2010 through 2014, we enrolled community-dwelling persons in Australia and the United States who were 70 years of age or older (or ≥65 years of age among blacks and Hispanics in the United States) and did not have cardiovascular disease, dementia, or disability. Participants were randomly assigned to receive 100 mg of enteric-coated aspirin or placebo. Deaths were classified according to the underlying cause by adjudicators who were unaware of trial-group assignments. Hazard ratios were calculated to compare mortality between the aspirin group and the placebo group, and post hoc exploratory analyses of specific causes of death were performed. RESULTS: Of the 19,114 persons who were enrolled, 9525 were assigned to receive aspirin and 9589 to receive placebo. A total of 1052 deaths occurred during a median of 4.7 years of follow-up. The risk of death from any cause was 12.7 events per 1000 person-years in the aspirin group and 11.1 events per 1000 person-years in the placebo group (hazard ratio, 1.14; 95% confidence interval [CI], 1.01 to 1.29). Cancer was the major contributor to the higher mortality in the aspirin group, accounting for 1.6 excess deaths per 1000 person-years. Cancer-related death occurred in 3.1% of the participants in the aspirin group and in 2.3% of those in the placebo group (hazard ratio, 1.31; 95% CI, 1.10 to 1.56). CONCLUSIONS: Higher all-cause mortality was observed among apparently healthy older adults who received daily aspirin than among those who received placebo and was attributed primarily to cancer-related death. In the context of previous studies, this result was unexpected and should be interpreted with caution. (Funded by the National Institute on Aging and others; ASPREE ClinicalTrials.gov number, NCT01038583 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw106 · Cited by 6,457
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Antman, E., Bassand, J.-P., Klein, W., Ohman, M., Lopez Sendon, J. L., Rydén, L., Simoons, M., & Tendera, M. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00804-4 · Cited by 4,821
Final Report on the Aspirin Component of the Ongoing Physicians' Health Study
Steering Committee of the Physicians' Health Study Research Group* (1989) · New England Journal of Medicine · doi:10.1056/nejm198907203210301 · Cited by 2,264
A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women
Ridker, P. M., Cook, N. R., Lee, I.-M., Gordon, D., Gaziano, J. M., Manson, J. E., Hennekens, C. H., & Buring, J. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050613 · Cited by 1,945
Rothwell, P. M., Fowkes, F. G. R., Belch, J. F., Ogawa, H., Warlow, C. P., & Meade, T. W. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62110-1 · Cited by 1,497
Randomised trial of prophylactic daily aspirin in British male doctors
Peto, R., Gray, R., Collins, R., Wheatley, K., Hennekens, C., Jamrozik, K., Warlow, C., Hafner, B., Thompson, E., Norton, S., et al. (1988) · BMJ · doi:10.1136/bmj.296.6618.313 · Cited by 1,166
Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly
McNeil, J. J., Wolfe, R., Woods, R. L., Tonkin, A. M., Donnan, G. A., Nelson, M. R., Reid, C. M., Lockery, J. E., Kirpach, B., Storey, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805819 · Cited by 1,139
Self-citationRoncaglioni, M. C. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03539-x · Cited by 999
Competing risks in epidemiology: possibilities and pitfalls
Andersen, P. K., Geskus, R. B., de Witte, T., & Putter, H. (2012) · International Journal of Epidemiology · doi:10.1093/ije/dyr213 · Cited by 985
Rothwell, P. M., Wilson, M., Price, J. F., Belch, J. F., Meade, T. W., & Mehta, Z. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60209-8 · Cited by 984
Belch, J., MacCuish, A., Campbell, I., Cobbe, S., Taylor, R., Prescott, R., Lee, R., Bancroft, J., MacEwan, S., Shepherd, J., et al. (2008) · BMJ · doi:10.1136/bmj.a1840 · Cited by 977
Bibbins-Domingo, K., & on behalf of the U.S. Preventive Services Task Force* (2016) · Annals of Internal Medicine · doi:10.7326/m16-0577 · Cited by 854
Decline in Cardiovascular Mortality: Possible Causes and Implications
Mensah, G. A., Wei, G. S., Sorlie, P. D., Fine, L. J., Rosenberg, Y., Kaufmann, P. G., Mussolino, M. E., Hsu, L. L., Addou, E., Engelgau, M. M., et al. (2017) · Circulation Research · doi:10.1161/circresaha.116.309115 · Cited by 847
Aspirin and the Risk of Colorectal Cancer in Relation to the Expression of COX-2
Chan, A. T., Ogino, S., & Fuchs, C. S. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067208 · Cited by 781
The Burden of Cardiovascular Disease in the Elderly: Morbidity, Mortality, and Costs
Yazdanyar, A., & Newman, A. B. (2009) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2009.07.007 · Cited by 666
Self-citationFowkes, F. G. R. (2010) · JAMA · doi:10.1001/jama.2010.221 · Cited by 624
Effect of aspirin on disability-free survival in the healthy elderly
McNeil, J. J., Woods, R. L., Nelson, M. R., Reid, C. M., Kirpach, B., Wolfe, R., Storey, E., Shah, R. C., Lockery, J. E., Tonkin, A. M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1800722 · Cited by 590
Self-citationAspirin and colorectal cancer: the promise of precision chemoprevention
Drew, D. A., Cao, Y., & Chan, A. T. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.4 · Cited by 453
Hennekens, C. H., Dyken, M. L., & Fuster, V. (1997) · Circulation · doi:10.1161/01.cir.96.8.2751 · Cited by 435
Li, L., Geraghty, O. C., Mehta, Z., & Rothwell, P. M. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30770-5 · Cited by 393
Study design of ASPirin in Reducing Events in the Elderly (ASPREE): A randomized, controlled trial
(2013) · Contemporary Clinical Trials · doi:10.1016/j.cct.2013.09.014 · Cited by 310
Ikeda, Y., Shimada, K., Teramoto, T., Uchiyama, S., Yamazaki, T., Oikawa, S., Sugawara, M., Ando, K., Murata, M., Yokoyama, K., et al. (2014) · JAMA · doi:10.1001/jama.2014.15690 · Cited by 301
Heart Disease and Cancer Deaths — Trends and Projections in the United States, 1969–2020
Weir, H. K., Anderson, R. N., Coleman King, S. M., Soman, A., Thompson, T. D., Hong, Y., Moller, B., & Leadbetter, S. (2016) · Preventing Chronic Disease · doi:10.5888/pcd13.160211 · Cited by 270
Guirguis-Blake, J. M., Evans, C. V., Senger, C. A., O'Connor, E. A., & Whitlock, E. P. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2113 · Cited by 260
Association of Aspirin Use With Major Bleeding in Patients With and Without Diabetes
De Berardis, G., Lucisano, G., D’Ettorre, A., Pellegrini, F., Lepore, V., Tognoni, G., & Nicolucci, A. (2012) · JAMA · doi:10.1001/jama.2012.5034 · Cited by 246
Andreotti, F., Rocca, B., Husted, S., Ajjan, R. A., ten Berg, J., Cattaneo, M., Collet, J.-P., De Caterina, R., Fox, K. A. A., Halvorsen, S., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv304 · Cited by 241
McNeil, J. J., Woods, R. L., Nelson, M. R., Murray, A. M., Reid, C. M., Kirpach, B., Storey, E., Shah, R. C., Wolfe, R. S., Tonkin, A. M., et al. (2017) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glw342 · Cited by 233
Self-citationWhitlock, E. P., Burda, B. U., Williams, S. B., Guirguis-Blake, J. M., & Evans, C. V. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2112 · Cited by 227
The Role of Aspirin in the Prevention of Cardiovascular Disease
Ittaman, S. V., VanWormer, J. J., & Rezkalla, S. H. (2014) · Clinical Medicine & Research · doi:10.3121/cmr.2013.1197 · Cited by 202
Meta-Analysis of Multiple Primary Prevention Trials of Cardiovascular Events Using Aspirin
Bartolucci, A. A., Tendera, M., & Howard, G. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.02.325 · Cited by 186
Effect of Aspirin on Mortality in the Primary Prevention of Cardiovascular Disease
Raju, N., Sobieraj-Teague, M., Hirsh, J., O'Donnell, M., & Eikelboom, J. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.01.018 · Cited by 169
Risk of Hemorrhagic Stroke With Aspirin Use: An Update
Gorelick, P. B., & Weisman, S. M. (2005) · Stroke · doi:10.1161/01.str.0000174189.81153.85 · Cited by 169
Ajani, U. A., Ford, E. S., Greenland, K. J., Giles, W. H., & Mokdad, A. H. (2006) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2005.08.042 · Cited by 158
Aspirin for Primary Cardiovascular Risk Prevention and Beyond in Diabetes Mellitus
Capodanno, D., & Angiolillo, D. J. (2016) · Circulation · doi:10.1161/circulationaha.116.023164 · Cited by 158
Saito, Y., Okada, S., Ogawa, H., Soejima, H., Sakuma, M., Nakayama, M., Doi, N., Jinnouchi, H., Waki, M., Masuda, I., et al. (2016) · Circulation · doi:10.1161/circulationaha.116.025760 · Cited by 156
Berger, J. S., Lala, A., Krantz, M. J., Baker, G. S., & Hiatt, W. R. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.04.006 · Cited by 145
Xie, M., Shan, Z., Zhang, Y., Chen, S., Yang, W., Bao, W., Rong, Y., Yu, X., Hu, F. B., & Liu, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090286 · Cited by 92
Mora, S., & Manson, J. E. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.2648 · Cited by 80
Gu, Q., Dillon, C. F., Eberhardt, M. S., Wright, J. D., & Burt, V. L. (2015) · Public Health Reports · doi:10.1177/003335491513000614 · Cited by 73
Nelson, M. R., Reid, C. M., Beilin, L. J., Donnan, G. A., Johnston, C. I., Krum, H., Storey, E., Tonkin, A. M., & McNeil, J. J. (2003) · Drugs & Aging · doi:10.2165/00002512-200320120-00004 · Cited by 72
Self-citationThe aspirin in reducing events in the elderly trial: Statistical analysis plan
Wolfe, R. S., Murray, A. M., Woods, R. L., Kirpach, B., Gilbertson, D. T., Shah, R. C., Nelson, M. R., Reid, C. M., Ernst, M. E., Lockery, J. E., et al. (2017) · International Journal of Stroke · doi:10.1177/1747493017741383 · Cited by 70
Self-citationNelson, M. R., Liew, D., Bertram, M., & Vos, T. (2005) · BMJ · doi:10.1136/bmj.38456.676806.8f · Cited by 54
Self-citationPrimary prevention of cardiovascular disease: new guidelines, technologies and therapies
Nelson, M. R., & Doust, J. A. (2013) · The Medical Journal of Australia · doi:10.5694/mja12.11054 · Cited by 39
Self-citationLatest statistics on cardiovascular disease in A ustralia
Waters, A., Trinh, L., Chau, T., Bourchier, M., & Moon, L. (2013) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12079 · Cited by 32
Updated Meta-Analysis of Aspirin in Primary Prevention of Cardiovascular Disease
Raju, N. C., Sobieraj‐Teague, M., Bosch, J., & Eikelboom, J. W. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.10.046 · Cited by 32
Margolis, K. L., Mahady, S. E., Nelson, M. R., Ives, D. G., Satterfield, S., Britt, C. J., Ekram, A. S., Lockery, J. E., Schwartz, E. C., Woods, R. L., et al. (2018) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2018.05.015 · Cited by 32
Self-citationAspirin for Stroke Prevention in Elderly Patients With Vascular Risk Factors
Uchiyama, S., Ishizuka, N., Shimada, K., Teramoto, T., Yamazaki, T., Oikawa, S., Sugawara, M., Ando, K., Murata, M., Yokoyama, K., et al. (2016) · Stroke · doi:10.1161/strokeaha.115.012461 · Cited by 30
The aspirin controversy in primary prevention
Raju, N. C., & Eikelboom, J. W. (2012) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e328356ae95 · Cited by 29
Lei, H., Gao, Q., Liu, S., & Xu, J. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00440 · Cited by 28
Aspirin for Cardioprotection and Strategies to Improve Patient Adherence
Duffy, D., Kelly, E. M., Trang, A., Whellan, D. J., & Mills, G. D. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.01.2721 · Cited by 27
Compliance with USPSTF recommendations on aspirin for prevention of cardiovascular disease in men
Malayala, S. V., & Raza, A. (2016) · International Journal of Clinical Practice · doi:10.1111/ijcp.12869 · Cited by 11
Alarmingly poor adherence to low-dose aspirin: a large population-based study
Singh, G., Arora, G., Mannalithara, A., Mithal, A., Sehgal, A., & Triadafilopoulos, G. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht308.p2522 · Cited by 3
Cited by
Inflammation and aging: signaling pathways and intervention therapies
Li, X., Li, C., Zhang, W., Wang, Y., Qian, P., & Huang, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01502-8 · Cited by 1,443
Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly
McNeil, J. J., Wolfe, R., Woods, R. L., Tonkin, A. M., Donnan, G. A., Nelson, M. R., Reid, C. M., Lockery, J. E., Kirpach, B., Storey, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805819 · Cited by 1,139
Self-citationEffect of aspirin on disability-free survival in the healthy elderly
McNeil, J. J., Woods, R. L., Nelson, M. R., Reid, C. M., Kirpach, B., Wolfe, R., Storey, E., Shah, R. C., Lockery, J. E., Tonkin, A. M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1800722 · Cited by 590
Self-citationZheng, S. L., & Roddick, A. J. (2019) · JAMA · doi:10.1001/jama.2018.20578 · Cited by 577
The quest to slow ageing through drug discovery
Partridge, L., Fuentealba, M., & Kennedy, B. K. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0067-7 · Cited by 468
Metadata
- Authors
- McNeil, J. J., Nelson, M. R., Woods, R. L., Lockery, J. E., Wolfe, R., Reid, C. M., Kirpach, B., Shah, R. C., Ives, D. G., Storey, E., Ryan, J., Tonkin, A. M., Newman, A. B., Williamson, J. D., Margolis, K. L., Ernst, M. E., Abhayaratna, W. P., Stocks, N., Fitzgerald, S. M., Orchard, S. G., Trevaks, R. E., Beilin, L. J., Donnan, G. A., Gibbs, P., Johnston, C. I., Radziszewska, B., Grimm, R., & Murray, A. M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-10-18
- Volume
- 379
- Issue
- 16
- Pages
- 1519-1528
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2889884522
- Cited by
- 813
- References
- 58
- FWCI
- 73.46
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.